Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer
| Autor: | Ismail, R. K., van Breeschoten, J., Wouters, M. W.J.M., van Dartel, M., van der Flier, S., Reyners, A. K.L., de Graeff, P., Pasmooij, A. M.G., de Boer, A., Broekman, K. E., Hilarius, D. L., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology |
|---|---|
| Přispěvatelé: | VU University medical center, Obstetrics and gynaecology, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Targeted Gynaecologic Oncology (TARGON), Guided Treatment in Optimal Selected Cancer Patients (GUTS) |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty Cancer Research Early discontinuation Receptor ErbB-2 Pyridines Advanced breast Breast Neoplasms Time to next treatment Palbociclib Piperazines Breast cancer ErbB-2 Older patients Breast Neoplasms/drug therapy Internal medicine Clinical outcomes Antineoplastic Combined Chemotherapy Protocols Medicine Humans In patient RC254-282 Aged Drug Tapering business.industry Cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens General Medicine Middle Aged Dose reductions medicine.disease Original Article Female Surgery Antineoplastic Combined Chemotherapy Protocols/therapeutic use business Receptor |
| Zdroj: | Breast, 60, 263-271. Churchill Livingstone Breast, Vol 60, Iss, Pp 263-271 (2021) Ismail, R K, van Breeschoten, J, Wouters, M W J M, van Dartel, M, van der Flier, S, Reyners, A K L, de Graeff, P, Pasmooij, A M G, de Boer, A, Broekman, K E & Hilarius, D L 2021, ' Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer ', Breast, vol. 60, pp. 263-271 . https://doi.org/10.1016/j.breast.2021.11.013 Breast, 60, 263. Churchill Livingstone The Breast, 60, 263-271. Churchill Livingstone The Breast : Official Journal of the European Society of Mastology |
| ISSN: | 0960-9776 |
| Popis: | Background This study aimed to provide insights into the real-world use of palbociclib, dose reductions, and drug effectiveness in (older) patients with advanced breast cancer (BC). Patients and methods Patients with advanced BC treated with palbociclib from 2017 to 2020 were included. The Kaplan-Meier method was used to calculate time to next treatment (TTNT) and overall survival (OS) for patients with or without dose reductions. These clinical outcomes were also compared in subgroup analyses for older patients (≥70 years) and younger patients ( Highlights • Palbociclib dose reductions occurred in 33% of the real-world patients. • Dose reductions did not lead to poorer overall survival. • Older patients had more dose reductions, but this did not affect overall survival. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect